Overview
- South Africa's health regulator has approved Sun Pharmaceutical to manufacture and sell a generic semaglutide injection for adults with inadequately controlled type 2 diabetes.
- Sun Pharma plans to launch pre-filled, multi-dose once-weekly pens in two strengths, 2 mg and 4 mg, in the coming days.
- This approval follows earlier clearance in India and comes after the originator's patent on semaglutide expired, opening the market to generic makers.
- The entry of a lower-cost, approved generic increases commercial pressure on Novo Nordisk and on Eli Lilly, which both sell competing diabetes and weight-loss drugs in South Africa.
- Regulators are tightening oversight of compounded semaglutide products as patients seek cheaper options, and broader generic entry could lower prices and improve access for many patients.